This is a first-in-human, single-center, randomized, double-blind, placebo-controlled clinical trial designed to:Evaluate the efficacy of JN002 Ophthalmic Solution in treating dry eye disease (DED)Assess the safety of JN002 Ophthalmic SolutionResearchers will compare three groups-placebo (vehicle), low-dose JN002 (0.05 mg/mL), and high-dose JN002 (0.1 mg/mL)-to evaluate whether JN002 Ophthalmic Solution improves DED outcomes and to assess its safety profile relative to placebo.Participants will:Complete a baseline assessment (V0) including ocular exams, OSDI questionnaire, and systemic evaluation;Administer the assigned study medication three times daily (1 drop per eye per administration);Attend three follow-up visits (V1: 72 days, V2: 142 days, V3: 282 days post-treatment initiation) for ocular assessments, symptom queries, and adherence checks;Undergo a full repeat of baseline assessments at V3 to evaluate treatment effects and safety profile